17 May 1989 Synchronous Fluorescence Studies Of Anthracycline Anti-Tumor Drugs
Author Affiliations +
Proceedings Volume 1054, Fluorescence Detection III; (1989) https://doi.org/10.1117/12.951552
Event: OE/LASE '89, 1989, Los Angeles, CA, United States
Abstract
Synchronous fluorescence (SF) is used to study structurally and spectrally similar anthracycline anti-tumor drugs in biological fluids and model membranes. SF bandwidths at half maxima are typically 20-24 nm versus 75-80 nm for unresolved spectra acquired during conventional scans. This substantial band-narrowing effect permits excellent resolution between Adriamycin and an interferant, 5- iminodaunorubicin, in a two-component mixture. SF detection limits for Adriamycin are 7 x 10-7 M in serum and 1.5 x 10-7 M in buffered aqueous solution. Additional studies of structurally homologous drugs in liposomes and organic solvents indicate that SF may be useful in characterizing the influence of substituent groups on relative membrane permeation depth.
© (1989) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Bruce J. Tromberg, Bruce J. Tromberg, Thomas G. Burke, Thomas G. Burke, James H. Doroshow, James H. Doroshow, Michael W. Berns, Michael W. Berns, } "Synchronous Fluorescence Studies Of Anthracycline Anti-Tumor Drugs", Proc. SPIE 1054, Fluorescence Detection III, (17 May 1989); doi: 10.1117/12.951552; https://doi.org/10.1117/12.951552
PROCEEDINGS
8 PAGES


SHARE
Back to Top